Please login to the form below

dermatitis

This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

dermatitis and as add-on maintenance therapy for asthma with an eosinophilic phenotype or in patients dependent on oral corticosteroids.

Latest news

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

Its most advanced programme is anti-OX40-Ligand (OX40L), which is now entering phase 2 development in atopic dermatitis, with results expected in the first half of 2020.
Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

REGN3500 is also being studied in phase 2 trials for chronic obstructive pulmonary disease and atopic dermatitis. ... The underwhelming results also hit shares of biotech AnaptysBio’s, which has its own IL-33 antibody therapy in development in atopic
Hudson named Brandicourt’s successor as Sanofi’s CEO

atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).
Havas Lynx poem for charity has women’s interests at heart

This has been through the use of a clever mix of creative, digital, social and video to raise awareness and challenge preconceptions around HIV, dermatitis and, more recently Parkinson’s.
Sanofi's Dupixent gains asthma approval in Europe

Already approved in atopic dermatitis, the drug can now be used an add-on maintenance treatment for asthma patients with type 2 inflammation. ... Dupixent is now approved in asthma and atopic dermatitis, and we continue to study this novel treatment in

More from news
Approximately 9 fully matching, plus 70 partially matching documents found.

Latest Intelligence

Innovation and digital health comms recognised at Communiqué Awards

The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative
Drug launches to watch in 2019

It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
Leo has its eyes on the prize

Psoriasis and dermatitis may seem the same in everybody but maybe the picture is more like it is in cancer where you have subsets. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across Europe while psoriasis levels show no signs of
Pharma deals continue to slide

Phase II MAb to block IL-13 for treatment of atopic dermatitis.
Deal Watch September 2016

as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

Dr Desiree Luthman joins Verona Pharma

atopic dermatitis in the US.
Ziarco appoints Mike Grey to board of directors

Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
Atopic Dermatitis — Going Beyond the Pill

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Research Partnership

Atopic Dermatitis — Going Beyond the Pill.

More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Strategic Planner, Healthcare Advertising Agency: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director – UK Office: Excellent salary and benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...